



1FW
D0284 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Melissa Handler, Ph.D.
Type or print name

Melissa Handler
Signature

September 5, 2006
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1653

STEVEN NADLER, ET AL.

EXAMINER: MONSHIPOURI, MARYAM

APPLICATION NO: 10/755,889

FILED: 01/13/2004

FOR: POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE
NF-KB PATHWAY

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Date: September 5, 2006

Melissa Handler
Melissa Handler, Ph.D.
Attorney for Applicant
Reg. No. 52,988
Phone: 609-252-4323



D0284 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Melissa Handler, Ph.D.
Type or print name

Melissa Handler
Signature

September 5, 2006
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**IN RE APPLICATION OF
STEVEN NADLER, ET AL.**

ART UNIT: 1653

EXAMINER: MONSHIPOURI, MARYAM

APPLICATION NO: 10/755,889

FILED: 01/13/2004

**FOR: POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH
THE NF-KB PATHWAY**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

09/08/2006 HDEMESS1 00000012 193880 10755889


01 FC:1806 180.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Date: September 5, 2006



Melissa Handler, Ph.D.
Attorney for Applicant
Reg. No. 52,988
Phone: 609-252-4323



Substitution for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S) <i>(use as many sheets as necessary)</i>		PTO/SB/08B (8/03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Sheet 1 of 1		COMPLETE IF KNOWN Application Number: 10/755,889 Filing Date: 01/13/2004 First Named Inventor: STEVEN NADLER Art Unit: 1653 Examiner Name: MONSHIPOURI, MARYAM Attorney Docket Number: D0284 NP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	1A	NCBI Entrez Accession No. AAC50054 (gi:392427), Ye, B.H. et al., December 6, 1993	
	1B	NCBI Entrez Accession No. AI624861 (gi:4649792), December 14, 1999	
	1C	NCBI Entrez Accession No. NP_001697 (gi:21040324), Atayar, C. et al., July 16, 2006	
	1D	NCBI Entrez Accession No. U00115 (gi:392426), Ye, B.H. et al., December 6, 1993	
	1E	Atayar, C. et al., "BCL6 alternative breakpoint region break and homozygous deletion of 17q24 in the nodular lymphocyte predominance type of Hodgkin's lymphoma-derived cell line DEV", Human Pathology, Vol. 37, No. 6, pp. 675-683 (2006)	
	1F	Baron, B.W. et al., "Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas", Proc. Natl. Acad. Sci. U.S.A., Vol. 90, No. 11, pp. 5262-5266 (1993)	
	1G	Lin, C.H. et al., "Comparison of the Expression and Prognostic Significance of Differentiation Markers between Diffuse Large B-Cell Lymphoma of Central Nervous System Origin and Peripheral Nodal Origin", Clin. Cancer Res., Vol. 12, No. 4, pp. 1152-1156 (2006)	
	1H	Malpeli, G. et al., "Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas", Haematologica, Vol. 89, No. 9, pp. 1091-1099 (2004)	
	1I	Margalit, O. et al., "BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma", Blood, Vol. 107, No. 4, pp. 1599-1607 (2006)	
	1J	Miles, R.R. et al., "Analysis of BCL6-interacting Proteins by Tandem Mass Spectrometry", Molecular & Cellular Proteomics, Vol. 4, No. 12, pp. 1898-1909 (2005)	
	1K	Pantano, S. et al., "Plastic downregulation of the transcriptional repressor BCL6 during maturation of human dendritic cells", Experimental Cell Research, Vol. 312, No. 8, pp. 1312-1322 (2006)	
	1L	Wlodarska, I. et al., "Heterogeneity of BCL6 rearrangements in nodular lymphocyte predominant Hodgkin's lymphoma", Haematologica, Vol. 89, No. 8, pp. 965-972 (2004)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant